GBL Joins CVC in €10.7bn Takeover Bid for Recordati

Why It Matters

The deal could reshape Europe’s pharma landscape by moving a fast‑growing specialty drugmaker into private hands, unlocking capital for aggressive expansion while testing investor appetite for high‑growth, risk‑laden assets.

Key Takeaways

• CVC and GBL lead €10.7bn consortium for Recordati.
• Recordati aims private ownership for faster M&A and licensing.
• Isturisa sales surged to €394m, doubling forecast to €1.2bn.
• Investors include ADIA’s Luxinva, CPPIB, and chairman Andrea Recordati.
• Analysts doubt offer price satisfies current shareholders.

Pulse Analysis

Private equity’s appetite for specialty pharmaceuticals has intensified, and CVC’s partnership with Belgian fund GBL underscores that trend. By consolidating a €10.7 billion (~$11.6 billion) bid, the consortium not only raises the stakes for Recordati but also signals confidence in the company’s pipeline, especially its flagship cortisol synthesis inhibitor, Isturisa. The inclusion of sovereign‑wealth and pension‑fund investors such as ADIA’s Luxinva and CPPIB adds financial depth, while the existing 46.8% stake held by CVC provides a familiar strategic anchor.

Recordati’s recent performance bolsters the case for a leveraged buyout. Revenue is projected to hit €2.62 billion (~$2.8 billion) in 2025, driven by an 8.3% growth rate and a surge in Isturisa sales to €394 million (~$425 million) last year. The drug’s forecast has doubled to €1.2 billion (~$1.3 billion), highlighting the company’s capacity to generate high‑margin specialty products. Private ownership would grant Recordati greater flexibility to pursue bolt‑on acquisitions and licensing deals without the scrutiny of public markets, a crucial advantage as it eyes expansion into rare‑disease therapeutics where competition and asset prices are rising.

Nevertheless, the bid faces headwinds. Analysts note that the €51.29‑per‑share offer (~$56) may undervalue the firm relative to its growth trajectory, potentially alienating current shareholders. If the deal closes before year‑end, it could set a precedent for further private‑equity incursions into European pharma, prompting a reassessment of valuation benchmarks for high‑growth, niche drug developers. The outcome will likely influence both the pace of consolidation in the sector and the strategic calculus of other investors weighing public versus private pathways for similar companies.